NCT00748579

Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

A Phase II Open-Label Study to Investigate the Effects of CK-1827452 Injection on Ventricular Performance, Myocardial Oxygen Consumption, and Myocardial Efficiency in Patients With Heart Failure and Left Ventricular Systolic Dysfunction

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Cytokinetics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart failure and to confirm that the unique preclinical pharmacological profile of CK- 1827452 is substantially the same in patients with heart failure.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	CK-1827452	I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
DRUG	CK-1827452	I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr

Timeline

• Start date: 2008-09-01
• Primary completion: 2008-11-01
• Completion: 2009-07-01
• First posted: 2008-09-08
• Last updated: 2020-01-21
• Results posted: 2010-08-23

Locations

3 sites across 2 countries: United States, Canada